Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
出版年份 2020 全文链接
标题
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 117, Issue 24, Pages 13428-13436
出版商
Proceedings of the National Academy of Sciences
发表日期
2020-06-04
DOI
10.1073/pnas.2001569117
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
- (2019) Wang Manni et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
- (2019) Daniel Shae et al. Nature Nanotechnology
- A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
- (2019) Takeshi Tanoue et al. NATURE
- Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.
- (2019) Matthew Reilley et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
- (2019) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-specific macrophage targeting through recognition of retinoid X receptor beta
- (2019) Tang Tang et al. JOURNAL OF CONTROLLED RELEASE
- Advances in cancer immunotherapy 2019 – latest trends
- (2019) Stephan Kruger et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Personalized RNA Medicine for Pancreatic Cancer
- (2018) Maud-Emmanuelle Gilles et al. CLINICAL CANCER RESEARCH
- Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer
- (2018) Srinivas R. Viswanathan et al. NATURE GENETICS
- Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
- (2018) Elisa Peranzoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Eradication of spontaneous malignancy by local immunotherapy
- (2018) Idit Sagiv-Barfi et al. Science Translational Medicine
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
- (2018) Mohammed Milhem et al. CANCER RESEARCH
- iRGD-guided tumor-penetrating nanocomplexes for therapeutic siRNA delivery to pancreatic cancer
- (2018) Justin H. Lo et al. MOLECULAR CANCER THERAPEUTICS
- LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
- (2018) K J Harrington et al. ANNALS OF ONCOLOGY
- CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
- (2017) Nobutaka Hanagata International Journal of Nanomedicine
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas
- (2017) Yin Ren et al. Scientific Reports
- A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
- (2017) Jeremy B. Foote et al. Cancer Immunology Research
- Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide–siRNA Nanocomplexes
- (2016) Justin H. Lo et al. BIOCONJUGATE CHEMISTRY
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- Abscopal effects of radiation therapy: A clinical review for the radiobiologist
- (2015) Shankar Siva et al. CANCER LETTERS
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
- (2015) Encouse B Golden et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Immunomodulatory spherical nucleic acids
- (2015) Aleksandar F. Radovic-Moreno et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
- (2015) Manuel Schmidt et al. Nucleic Acid Therapeutics
- Intratumoral Immunization: A New Paradigm for Cancer Therapy
- (2014) A. Marabelle et al. CLINICAL CANCER RESEARCH
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2014) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Structure-based programming of lymph-node targeting in molecular vaccines
- (2014) Haipeng Liu et al. NATURE
- Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
- (2014) Theerawut Chanmee et al. Cancers
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
- (2013) B. Kwong et al. CANCER RESEARCH
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
- (2013) Sandra Demaria et al. OncoImmunology
- Identification and Characterization of Receptor-Specific Peptides for siRNA Delivery
- (2012) Yin Ren et al. ACS Nano
- Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4
- (2012) Y. Ren et al. Science Translational Medicine
- Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy
- (2011) Brandon Kwong et al. BIOMATERIALS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Targeting of drugs and nanoparticles to tumors
- (2010) Erkki Ruoslahti et al. JOURNAL OF CELL BIOLOGY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- The contribution of direct TLR signaling to T cell responses
- (2009) Adeeb H. Rahman et al. IMMUNOLOGIC RESEARCH
- Mitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma
- (2008) V. Fogal et al. CANCER RESEARCH
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started